Search research articles
Contact Us
Filters
Showing results (91-100 of 106) with videos related to
Page
of 11
Sort By:
Breast Cancer Research and Treatment
|
April 11, 2020
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy
Karin Ribi, Weixiu Luo, Barbara A Walley, et al.
Breast Cancer Research and Treatment
|
May 4, 2015
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
Brian Leyland-Jones, Kathryn P Gray, Mark Abramovitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2017
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials
Poornima Saha, Meredith M Regan, Olivia Pagani, et al.
The Lancet. Oncology
|
March 16, 2013
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial
Viviana Galimberti, Bernard F Cole, Stefano Zurrida, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2016
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial
Karin Ribi, Weixiu Luo, Jürg Bernhard, et al.
The New England Journal of Medicine
|
March 12, 2004
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
R Charles Coombes, Emma Hall, Lorna J Gibson, et al.
British Journal of Cancer
|
January 18, 2020
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
Karin Ribi, Weixiu Luo, Marco Colleoni, et al.
British Journal of Cancer
|
April 11, 2019
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
Karin Ribi, Weixiu Luo, Marco Colleoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2022
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials
Olivia Pagani, Barbara A Walley, Gini F Fleming, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 27, 2018
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
Thomas Ruhstaller, Anita Giobbie-Hurder, Marco Colleoni, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 106) with videos related to
Sort By:
Page
of 11
Breast Cancer Research and Treatment
|
April 11, 2020
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy
Karin Ribi, Weixiu Luo, Barbara A Walley, et al.
Breast Cancer Research and Treatment
|
May 4, 2015
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
Brian Leyland-Jones, Kathryn P Gray, Mark Abramovitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2017
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials
Poornima Saha, Meredith M Regan, Olivia Pagani, et al.
The Lancet. Oncology
|
March 16, 2013
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial
Viviana Galimberti, Bernard F Cole, Stefano Zurrida, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2016
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial
Karin Ribi, Weixiu Luo, Jürg Bernhard, et al.
The New England Journal of Medicine
|
March 12, 2004
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
R Charles Coombes, Emma Hall, Lorna J Gibson, et al.
British Journal of Cancer
|
January 18, 2020
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
Karin Ribi, Weixiu Luo, Marco Colleoni, et al.
British Journal of Cancer
|
April 11, 2019
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
Karin Ribi, Weixiu Luo, Marco Colleoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2022
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials
Olivia Pagani, Barbara A Walley, Gini F Fleming, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 27, 2018
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
Thomas Ruhstaller, Anita Giobbie-Hurder, Marco Colleoni, et al.
Page
of 11